re: #326 John Hughes

I just don’t see the problem….

If the trial is run without at-risk people then you can’t really tell if it works.

…

This is the core of the problem, which is touched further up the thread. If the purpose is to develop a preventive, preventing infection in the young healthy sample does the job. If it fails in that sample, the consequences are bad enough, but far less deadly. Nothing much is learned by failing on a sample we know is more brittle.